March 3, 2026Open Access

Glymphatic system dysfunction and cognitive impairment in post-chemotherapy AML: A novel DTI-ALPS index study

Key Points

Cognitive impairment correlates with glymphatic system dysfunction in post-chemotherapy AML patients, highlighting a crucial link.
The study identifies the DTI-ALPS index and BG-PVS volume as important neuroimaging biomarkers associated with cognitive decline.
Using advanced neuroimaging techniques, the research examines glymphatic function in AML patients after chemotherapy.
These findings emphasize the need to address cognitive health in AML patients, particularly after chemotherapy treatment.

Abstract

Post-chemotherapy AML patients exhibit glymphatic system dysfunction and cognitive decline, with a significant association between these alterations. Impairment in glymphatic function, as suggested by these biomarkers, may contribute to cognitive deficits in this context. The DTI-ALPS index and BG-PVS volume represent potential neuroimaging biomarkers, providing new insights into chemotherapy-related cognitive impairment in AML.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Li et al. (Sat,) studied this question.

synapsesocial.com/papers/69a7612fc6e9836116a2ede8 https://doi.org/https://doi.org/10.1016/j.brainresbull.2026.111777

Bookmark

View Full Paper